Thrombotargets Corporation - Product Pipeline Review - 2014

Date: September 15, 2014
Pages: 23
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T5E84C7FFF8EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Thrombotargets Corporation - Product Pipeline Review - 2014’, provides an overview of the Thrombotargets Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Thrombotargets Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Thrombotargets Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Thrombotargets Corporation’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Thrombotargets Corporation’s pipeline products
Reasons to buy
  • Evaluate Thrombotargets Corporation’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Thrombotargets Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Thrombotargets Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Thrombotargets Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Thrombotargets Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Thrombotargets Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Thrombotargets Corporation Snapshot
Thrombotargets Corporation Overview
Key Information
Key Facts
Thrombotargets Corporation - Research and Development Overview
Key Therapeutic Areas
Thrombotargets Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Thrombotargets Corporation - Pipeline Products Glance
Thrombotargets Corporation - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Thrombotargets Corporation - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Thrombotargets Corporation - Drug Profiles
TT-173
Product Description
Mechanism of Action
R&D Progress
TT-105
Product Description
Mechanism of Action
R&D Progress
TT-111
Product Description
Mechanism of Action
R&D Progress
TT-112
Product Description
Mechanism of Action
R&D Progress
TT-120
Product Description
Mechanism of Action
R&D Progress
Thrombotargets Corporation - Pipeline Analysis
Thrombotargets Corporation - Pipeline Products by Route of Administration
Thrombotargets Corporation - Pipeline Products by Molecule Type
Thrombotargets Corporation - Recent Pipeline Updates
Thrombotargets Corporation - Dormant Projects
Thrombotargets Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Thrombotargets Corporation, Key Information
Thrombotargets Corporation, Key Facts
Thrombotargets Corporation - Pipeline by Indication, 2014
Thrombotargets Corporation - Pipeline by Stage of Development, 2014
Thrombotargets Corporation - Monotherapy Products in Pipeline, 2014
Thrombotargets Corporation - Phase II, 2014
Thrombotargets Corporation - Preclinical, 2014
Thrombotargets Corporation - Discovery, 2014
Thrombotargets Corporation - Pipeline by Route of Administration, 2014
Thrombotargets Corporation - Pipeline by Molecule Type, 2014
Thrombotargets Corporation - Recent Pipeline Updates, 2014
Thrombotargets Corporation - Dormant Developmental Projects,2014
Thrombotargets Corporation, Other Locations

LIST OF FIGURES

Thrombotargets Corporation - Pipeline by Top 10 Indication, 2014
Thrombotargets Corporation - Pipeline by Stage of Development, 2014
Thrombotargets Corporation - Monotherapy Products in Pipeline, 2014
Thrombotargets Corporation - Pipeline by Top 10 Molecule Type, 2014
Skip to top


Ask Your Question

Thrombotargets Corporation - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: